The vision of OncoSynergy, a UCSF spin-out, is to radically improve outcomes for patients with unmet needs in oncology with Resistance Mechanism Inhibitors (RMIs). This new class of therapeutics simultaneously targets multiple hallmarks of cancer progression and have demonstrated dramatic preclinical efficacy as monotherapy and in strategic combinations.
Area of focus: Therapeutics/Oncology
Commencement date: May, 2017
Location: JLABS @ SSF